A review of oncolytic viruses in cancer treatment

Oncolytic viruses (OVs) are becoming more significant in the treatment of cancer. Oncolytic viruses provide an appealing therapeutic combination of tumor-specific cell destruction and immune activation, making them potential in situ cancer vaccines. OVs may also be modified to improve tumor selectivity and immune stimulation, and they can be easily coupled with other medicines. The efficacy of OVs has been shown in many preclinical trials and, most recently, in people, with the approval of the oncolytic herpes virusestalimo gene laherparepvec in metastatic melanoma by the US United States Food and drug, a significant milestone for the field. As a result, scientists, doctors, and the general public are growing increasingly interested in the OV approach to cancer treatment. The primary goal of this study is to offer a general overview of OVs in clinical development as well as a description of where clinical trials are now.